Suppr超能文献

合成和天然产物作为铁螯合剂。

Synthetic and natural products as iron chelators.

机构信息

Centre for Metals in Biology, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane 4072, Queensland, Australia.

出版信息

Curr Top Med Chem. 2011;11(5):591-607. doi: 10.2174/156802611794785163.

Abstract

An evaluation of existing and proposed Fe chelators, both synthetic and natural products, for the treatment of Fe-overload disease must address a number of issues. There are fundamental parameters that determine the efficacy of a drug: absorption, distribution, metabolism, clearance and toxicity. However, the administration of chelator for Fe overload aims to generate Fe complexes in vivo that are able to be excreted. Hence, the chemical and pharmacological properties of the complexes formed are equally important as the chelators themselves. The redox properties of the Fe complexes formed is particularly relevant to their toxicity. If both Fe(II) and Fe(III) oxidation states of the complexes are biologically accessible, then there is potential for the auto-catalytic production of deleterious free radicals, by Fenton-type chemistry. In addition, since the burden of Fe overload disease falls predominantly on some of the poorest economies, the cost of a drug must be considered, as well as the mode of delivery. There are also possible issues with the use of naturally occurring ligands, which may form Fe complexes capable of being utilised by opportunistic bacteria. This review will concentrate on recent developments in our chemical understanding of existing chelators approved or proposed for use and will also consider some of the candidates from natural sources that have been recently proposed.

摘要

评估现有的和拟议的铁螯合剂,包括合成和天然产物,用于治疗铁过载疾病,必须解决许多问题。有一些基本参数决定了药物的疗效:吸收、分布、代谢、清除和毒性。然而,铁螯合剂治疗铁过载的目的是在体内产生能够被排泄的铁复合物。因此,形成的复合物的化学和药理学性质与螯合剂本身同样重要。形成的铁复合物的氧化还原性质与其毒性特别相关。如果复合物的 Fe(II)和 Fe(III)氧化态都具有生物可及性,那么就有可能通过 Fenton 型化学产生有害的自由基。此外,由于铁过载疾病的负担主要落在一些最贫穷的经济体上,因此必须考虑药物的成本以及给药方式。天然配体的使用也可能存在问题,因为它们可能形成能够被机会性细菌利用的铁复合物。本综述将集中讨论我们对现有螯合剂的化学理解的最新进展,这些螯合剂已被批准或拟用于治疗铁过载疾病,同时还将考虑一些最近提出的天然来源的候选药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验